Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesADMA Biologics Inc

ADMA Biologics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
12.73 USD 0.00(0%)
Last update at 2026-11-06T21:00:00Z
VOLUME
4641960
Market Cap
1928.51M
P/E
12.30

Momentum Score

…

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
12.53
Low
13.20
High
52 Week Price Range
7.21
Low
20.46
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

ADMA Biologics develops, manufactures and commercializes plasma-derived immune globulin products intended to treat primary immunodeficiency and certain infectious diseases. Long-term growth may be supported by rising demand for immunoglobulin therapies, commercialization of its approved products and potential label expansions and contract sales that could increase recurring revenue.

Key risks include operational and regulatory challenges in plasma collection and manufacturing, dependence on third-party plasma suppliers, competition from larger plasma companies, reimbursement pressures, and limited financial resources that could constrain commercialization and development.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
12.73
Dividend Yield
-
Revenue TTM
512.28M
Revenue Per Share
2.18
Gross Profit TTM
331.47M
Debt / Equity
0.17
ROE
41.90%
Net Debt
-7.75M
ROCE
34.21%
Diluted EPS TTM
0.70

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 182.66M 125.71M -28.24M -65.90M -71.65M
Net income 146.93M 197.67M -28.24M -85.18M -84.45M
Selling general administrative 91.58M 74.12M 57.38M 70.30M 55.19M
Gross profit 292.76M 219.55M 88.94M 35.27M 1.17M
Reconciled depreciation 8.10M 8.04M 8.16M 7.11M 5.50M
Ebit 189.77M 139.64M -3.21M -39.37M -58.37M
Ebitda 197.86M 147.69M 5.12M -39.24M -57.88M
Depreciation and amortization 8.10M 8.04M 8.33M 0.13M 0.50M
Non operating income net other - - - -7.26M -0.22M
Operating income 191.44M 138.98M 21.63M -39.37M -58.37M
Other operating expenses 318.73M 287.47M 236.58M 193.44M 139.32M
Interest expense 7.11M 13.93M 25.03M 19.28M 13.06M
Tax provision 35.73M -71.96M 0.00M - -
Interest income 1.87M 2.10M 1.01M 0.04M 0.03M
Net interest income -5.24M -11.83M -23.54M -19.23M -13.02M
Income tax expense 35.73M -71.96M 8.16M 19.28M 12.81M
Total revenue 510.17M 426.45M 258.21M 154.08M 80.94M
Total operating expenses 101.32M 80.57M 67.31M 74.63M 59.55M
Cost of revenue 217.41M 206.90M 169.27M 118.81M 79.77M
Total other income expense net -8.79M -13.27M -49.87M -26.54M -13.27M
Net income from continuing ops 146.93M 197.67M -22.83M -65.90M -71.65M
Net income applicable to common shares - - - -65.90M -71.65M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 624.24M 488.68M 329.18M 348.46M 276.25M
Intangible assets 0.63M 0.46M 0.50M 1.01M 1.73M
Other current assets 13.99M 8.03M 5.33M 5.10M 4.34M
Total liab 146.92M 139.66M 193.98M 196.49M 135.08M
Total stockholder equity 477.32M 349.02M 135.21M 151.97M 141.17M
Other current liab 41.71M 30.48M 32.92M 24.99M 17.21M
Common stock 0.02M 0.02M 0.02M 0.02M 0.02M
Capital stock 0.02M 0.02M 0.02M 0.02M 0.02M
Retained earnings -161.65M -308.58M -506.26M -478.02M -412.11M
Other liab - - - 3.68M 2.37M
Good will 3.53M 3.53M 3.53M 3.53M 3.53M
Other assets - - 0.00M 4.77M 4.07M
Cash 87.63M 103.15M 51.35M 86.52M 51.09M
Total current liabilities 69.54M 55.54M 49.81M 39.27M 30.38M
Current deferred revenue 1.41M 0.14M 0.18M 0.14M 0.14M
Net debt -7.75M -21.03M 90.07M 67.92M 51.83M
Short term debt 3.91M 1.22M 1.04M 0.91M 0.59M
Short long term debt 2.81M - - - -
Short long term debt total 79.89M 82.12M 141.42M 154.44M 102.92M
Other stockholder equity 638.95M 657.58M 641.44M 629.97M 553.27M
Property plant equipment - - - 58.26M 50.94M
Total current assets 466.51M 331.41M 257.01M 270.40M 208.73M
Net tangible assets - - - 151.97M 141.17M
Net receivables 158.43M 50.00M 27.42M 15.51M 28.58M
Long term debt 69.33M 72.34M 130.59M 142.83M 94.87M
Inventory 206.47M 170.24M 172.91M 163.28M 124.72M
Accounts payable 22.52M 20.22M 15.66M 13.23M 12.43M
Common stock total equity - - - 0.02M 0.02M
Retained earnings total equity - - - -478.02M -412.11M
Non currrent assets other 8.60M 5.66M 4.67M 4.77M 4.07M
Non current assets total 157.73M 157.27M 72.17M 78.06M 67.52M
Capital lease obligations 7.74M 9.78M 10.82M 11.61M 8.05M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -8.57M -7.32M -13.91M -13.51M
Change to liabilities - - - 7.83M 9.92M
Total cashflows from investing activities -21.89M -8.57M -4.98M -13.91M -13.51M
Net borrowings -0.94M -60.00M -23.60M 48.97M -0.03M
Total cash from financing activities -44.02M -58.30M -38.99M 108.85M 121.05M
Change to operating activities - - - 6.40M 5.49M
Net income 146.93M 197.67M -28.24M -65.90M -71.65M
Change in cash -15.52M 51.80M -35.17M 35.43M -4.83M
Begin period cash flow 103.15M 51.35M 86.52M 51.09M 55.92M
End period cash flow 87.63M 103.15M 51.35M 86.52M 51.09M
Total cash from operating activities 50.40M 118.67M 8.80M -59.51M -112.37M
Issuance of capital stock - 0.00M 0.00M 64.65M 121.14M
Depreciation 8.10M 8.04M 8.33M 7.11M 5.50M
Other cashflows from investing activities -0.32M -0.35M -0.21M - -
Change to inventory -36.23M 2.67M -9.63M -38.56M -43.19M
Change to account receivables -108.43M -22.58M -11.92M 13.07M -15.34M
Sale purchase of stock -31.94M - -1.42M 64.82M 121.14M
Other cashflows from financing activities -11.89M -5.80M -13.97M 144.24M -0.06M
Change to netincome - - - 15.31M 3.71M
Capital expenditures 22.57M 8.57M 4.98M 13.91M 13.51M
Change receivables - - - 13.07M -15.34M
Cash flows other operating - - - -0.63M -3.07M
Cash and cash equivalents changes - - - 35.43M -4.83M
Change in working capital -139.59M -18.54M -10.12M -18.29M -51.68M
Stock based compensation 20.03M 13.62M 6.19M 5.21M 3.49M
Other non cash items 3.92M 2.16M 32.64M 12.35M 1.75M
Free cash flow 27.82M 110.10M 3.82M -73.42M -125.88M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ADMA
ADMA Biologics Inc		 -
-%		 12.73 12.30 9.23 3.76 5.01 4.13 9.08
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

465 State Route 17, Ramsey, NJ, United States, 07446

201 478 5552

https://www.admabiologics.com

640

Name Title Year Born
Mr. Adam S. Grossman Co-Founder, Pres, CEO & Director 1977
Dr. Jerrold B. Grossman D.P.S., Ph.D. Co-Founder & Vice Chairman 1948
Mr. Brian Lenz CPA, CPA Exec. VP, CFO & GM of ADMA BioCenters 1972
Ms. Kaitlin Kestenberg VP of Compliance, Project Management & Clinical Operations NA
Mr. Michael Goldstein Sr. Director & Gen. Counsel NA
Mr. Michael Least VP of Sales & Commercial Operations NA
Mr. Drew Pantello VP of Marketing & Corp. Devel. NA
Mr. Neal C. Fitzpatrick VP of Sales NA
Dr. Gene A. Wetzstein BCOP, Pharm.D. Exec. Director & Head of Scientific Engagement NA
Ms. Cyndi Tolman Sr. VP of Plasma Services NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.19%

  • Communication Services

    -0.04%

  • Consumer Cyclical

    +0.27%

  • Consumer Defensive

    -0.21%

  • Energy

    +1.16%

  • Financial Services

    +0.81%

  • Healthcare

    +0.03%

  • Industrials

    +1.64%

  • Real Estate

    +0.06%

  • Technology

    +0.38%

  • Utilities

    +0.68%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…